

KAREN L. CRUEY, M. D.
PSYCHIATRIC MEDICINE

Specialist in
• Child and Adolescent
Adult Psychiatry
Psychotherapy
Independent Medical Evaluations

2340 Paseo del Prado, D303
Las Vegas, NV 89102
(702) 247-1703
Fax (702) 247-4082
administrative cellular (702)219-4584

November 19, 2021

Pharmacy and Therapeutics Committee
State of Nevada Department of Health and Human Services
Division of Health Care Financing and Policy
1100 E. William Street, Suite 101
Carson City, NV 89701

Re: Agenda Item 5.f., Discussion and possible adoption of psychotropic agents-
antipsychotics-atypical antipsychotics, oral.

To Whom It May Concern:

I understand that Nevada Medicaid will review oral atypical antipsychotics for the Preferred Drug List at the December 9, 2021, Therapeutics Committee meeting. I request that the committee add Caplyta (lumateperone) to the State of Nevada Formulary for schizophrenia.

Caplyta has helped a number of my patient with schizophrenia including at least one with chronic, refractory symptoms, previously incarcerated for years because of psychosis-related violent behaviors, who has become much more organized and functional in the community. A young male adult special-needs patient with schizophrenia has become much calmer, stopped hitting his care provider, sleeps well for the first time in months, and speaks much more where previously he spoke little. My patients have not gained weight. The simplicity of once-a-day dosing with no titration required benefits both patient and prescriber.

I appreciate your consideration in adding this important new medication to the State of Nevada Formulary.

Respectfully submitted,



Karen L. Cruey, M.D.
Adult, Adolescent & Child Psychiatry
Nevada Medical License 8506